Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: A prospective cohort pilot feasibility study

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Darling, Chad E ^a   Mercado, Javier A Sala ^b,c   Quiroga Castro, Walter ^c   Tecco, Gabriel F ^c   Zelaya, Felix R ^c   Conci, Eduardo C ^c   Sala, Jose P ^c   Smith, Craig S ^a   Michelson, Alan D ^d   Whittaker, Peter ^a,b   Welch, Robert D ^b   Przyklenk, Karin ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Instituto Modelo de Cardiología Privado de Córdoba   (Argentina)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; ANEMIA; ARGENTINA; ARTICLE; BLOOD CLOT LYSIS; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; EMERGENCY WARD; FEASIBILITY STUDY; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONCARDIAC CHEST PAIN; PILOT STUDY; PLATELET REACTIVITY; POINT OF CARE TESTING; PREDICTIVE VALUE; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; BLOOD; EMERGENCY HEALTH SERVICE; HOSPITAL INFORMATION SYSTEM; THROMBOCYTE ACTIVATION; TIME;

ACUTE CORONARY SYNDROME; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET ACTIVATION; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84892858723     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003883     Document Type: Article

References (42)

1. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation 2010;122:1756-76.
2. Darling CE, Michelson AD, Volturo GA, et al. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. J Thromb Thrombolysis 2009;28:31-7.
3. Hollander JE, Chang AM, Shofer FS, et al. Coronary computed tomographic angiography for rapid discharge of low-risk patients with potential acute coronary syndromes. Ann Emerg Med 2009;53:295-304.
4. Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med 2012;366:1393-403.
5. Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 2012;367:299-308.
6. Hoffmann U, Truong QA, Fleg JL, et al. Design of the rule out myocardial ischemia/infarction using computer assisted tomography: a multicenter randomized comparative effectiveness trial of cardiac computed tomography versus alternative triage strategies in patients with acute chest pain in the emergency department. Am Heart J 2012;163:330-8, 8 e1.
7. Singer AJ, Domingo A, Thode HC Jr, et al. Utilization of coronary computed tomography angiography for exclusion of coronary artery disease in ED patients with low-to-intermediate-risk chest pain: a 1-year experience. Am J Emerg Med 2012;30:1706-11.
8. Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol 2013;61:880-92.
9. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999;33:634-9.
10. Linden MD, Furman MI, Frelinger AL III, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761-5. (Pubitemid 46563575)
11. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34. (Pubitemid 350007957)
12. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther 2009;14:157-69.
13. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010;9:154-69.
14. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol 2013;61:1-11.
15. Hollander JE, Muttreja MR, Dalesandro MR, et al. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol 1999;34:95-105.
16. Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-8. (Pubitemid 28153455)
17. Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of platelet function by flow cytometry. Methods 2000;21:259-70. (Pubitemid 32896750)
18. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009;103:20A-6A.
19. Crescente M, Mezzasoma AM, Del Pinto M, et al. Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets 2011;22:179-87.
20. Linnemann B, Schwonberg J, Rechner AR, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010;89:597-605.
21. Poulsen TS, Jorgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007;119:555-62. (Pubitemid 46321503)
22. Poulsen TS, Mickley H, Korsholm L, et al. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. Thromb Res 2007;120:161-72. (Pubitemid 46754409)
23. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42. (Pubitemid 30643610)
24. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:529-55.
25. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-35.
26. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e663-828.
27. Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med 2013:Epub 2 April 2013.
28. Kerr KF, Wang Z, Janes H, et al. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 2014;25:114-21.
29. Kelly AM. What is the incidence of major adverse cardiac events in emergency department chest pain patients with a normal ECG, thrombolysis in myocardial infarction score of zero and initial troponin <=99th centile: an observational study? Emerg Med J 2013;30:15-18.
30. Bernardi V, Szarfer J, Summay G, et al. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent (RACS) trial). Am J Cardiol 2007;99:349-52. (Pubitemid 46149552)
31. Bernztein RG, Drake I. Use of aspirin in the public primary care level: experience of the Remediar Program, Argentina. Rev Argent Cardiol 2010;78:330-8.
32. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
33. Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008;19:104-10. (Pubitemid 351302380)
34. Atiemo AD, Ng'Alla LS, Vaidya D, et al. Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis 2008;25:173-8. (Pubitemid 351583666)
35. Bevilacqua S, Alkodami AA, Volpi E, et al. Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function. Ann Thorac Surg 2009;87:496-502.
36. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
37. Breet NJ, van Werkum JW, Bouman HJ, et al. The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction. Thromb Haemost 2011;106:331-6.
38. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
39. Ang L, Thani KB, Ilapakurti M, et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol 2013;61:23-34.
40. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-7. (Pubitemid 39238016)
41. Harrison P, Mackie I, Mathur A, et al. Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 2005;16:557-62. (Pubitemid 41658974)
42. Moran A, Degennaro V, Ferrante D, et al. Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model. Int J Cardiol 2011;150:332-7.